The aim of this study was to compare the treatment outcomes of patients with de novo lesions in small coronary vessels undergoing percutaneous coronary intervention (pci) in sweden from april 2009 to july 2017 with drug-coated balloons (dcbs) or newer-generation drug-eluting stents (n-des).The in.Pact falcon was one brand of dcb used to treat patients in the dcb group within the study population.Patients included in the comparator n-des group were implanted with endeavor resolute, resolute integrity, and resolute onyx stents as well as the old-generation endeavor zotarolimus-eluting stent.A number of non-medtronic stents were also implanted in patients within this n-des group.14,788 patients with small-vessel cad were enrolled in the study: 1,154 were treated with dcbs and 13,634 with n-des.Altogether, 35,541 lesions were treated using 2,503 dcbs and 33,038 n-des.At a 3 year follow up, patients were assessed for the occurrence in the primary outcomes of restenosis and definite target lesion thrombosis and in secondary outcomes of all-cause death and myocardial infarction.Clinical outcomes reported in the study population included death, myocardial infarction, target lesion thrombosis, and restenosis.
|